Boston Scientific Corp. (NYSE:BSX) must include the potential for stent "shrinkage" in the labeling for its newly cleared Promus Element drug-eluting stent.
The decision comes as concerns mount that certain thinner, more flexible next-generation stents may be prone to crumpling after deployment, creating clots in blood vessels that may lead to heart attack.